Literature DB >> 33622402

Prognostic value of lymphocyte counts in bronchoalveolar lavage fluid in patients with acute respiratory failure: a retrospective cohort study.

Yasutaka Hirasawa1, Taka-Aki Nakada2, Takashi Shimazui3, Mitsuhiro Abe1, Yuri Isaka1, Masashi Sakayori1, Kenichi Suzuki1, Keiichiro Yoshioka1, Takeshi Kawasaki1, Jiro Terada1, Kenji Tsushima4, Koichiro Tatsumi1.   

Abstract

BACKGROUND: Cellular patterns in bronchoalveolar lavage fluid (BALF) are used to distinguish or rule out particular diseases in patients with acute respiratory failure (ARF). However, whether BALF cellular patterns can predict mortality or not is unknown. We test the hypothesis that BALF cellular patterns have predictive value for mortality in patients with ARF.
METHODS: This was a retrospective single-center observational study conducted in a Japanese University Hospital. Consecutive patients (n = 78) with both pulmonary infiltrates and ARF who were examined by bronchoalveolar lavage (BAL) between April 2015 and May 2018 with at least 1 year of follow-up were analyzed. Primary analysis was receiver operating characteristic curve-area under the curve (ROC-AUC) analysis for 1-year mortality.
RESULTS: Among the final sample size of 78 patients, survivors (n = 56) had significantly increased lymphocyte and eosinophil counts and decreased neutrophil counts in BALF compared with non-survivors (n = 22). Among the fractions, lymphocyte count was the most significantly different (30 [12-50] vs. 7.0 [2.9-13]%, P <0.0001). In the ROC curve analysis of the association of BALF lymphocytes with 1-year mortality, the AUC was 0.787 (P <0.0001, cut-off value [Youden index] 19.0%). Furthermore, ≥20% BALF lymphocytes were significantly associated with increased survival with adjustment for baseline imbalances (1-year adjusted hazard ratio, 0.0929; 95% confidence interval, 0.0147-0.323, P <0.0001; 90-day P =0.0012). Increased survival was significantly associated with ≥20% BALF lymphocytes in both interstitial lung disease (ILD) and non-ILD subgroups (P =0.0052 and P =0.0033, respectively). In secondary outcome analysis, patients with ≥20% BALF lymphocytes had significantly increased ventilator-free days, which represents less respiratory dysfunction than those with <20% BALF lymphocytes.
CONCLUSIONS: In the patients with ARF, ≥20% lymphocytes in BALF was associated with significantly less ventilatory support, lower mortality at both 90-day and 1-year follow-ups.

Entities:  

Keywords:  Acute respiratory failure; Bronchoalveolar lavage fluid; Lymphocytes; Mortality

Year:  2021        PMID: 33622402     DOI: 10.1186/s40560-021-00536-w

Source DB:  PubMed          Journal:  J Intensive Care        ISSN: 2052-0492


  2 in total

1.  Bronchoalveolar lavage in extrinsic allergic alveolitis: effect of time elapsed since antigen exposure.

Authors:  M Drent; H van Velzen-Blad; M Diamant; S S Wagenaar; H C Hoogsteden; J M van den Bosch
Journal:  Eur Respir J       Date:  1993-10       Impact factor: 16.671

2.  Mast cells, atypical lymphocytes, and neutrophils in bronchoalveolar lavage in extrinsic allergic alveolitis. Comparison with other interstitial lung diseases.

Authors:  P L Haslam; A Dewar; P Butchers; Z S Primett; A Newman-Taylor; M Turner-Warwick
Journal:  Am Rev Respir Dis       Date:  1987-01
  2 in total
  2 in total

1.  Prognostic implication of bronchoalveolar lavage fluid analysis in patients with Pneumocystis jirovecii pneumonia without human immunodeficiency virus infection.

Authors:  Chiwook Chung; Chae Man Lim; Yeon-Mok Oh; Sang Bum Hong; Chang-Min Choi; Jin Won Huh; Sei Won Lee; Jae Seung Lee; Kyung-Wook Jo; Wonjun Ji; Chan-Jeoung Park; Mina Kim; Heungsup Sung; Young-Uk Cho; Hyo Sin Cho; Ho Cheol Kim
Journal:  BMC Pulm Med       Date:  2022-06-26       Impact factor: 3.320

2.  High neutrophils and low lymphocytes percentages in bronchoalveolar lavage fluid are prognostic factors of higher in-hospital mortality in diffuse alveolar hemorrhage.

Authors:  Kensuke Kanaoka; Seigo Minami; Shoichi Ihara; Kiyoshi Komuta
Journal:  BMC Pulm Med       Date:  2021-09-09       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.